Table 1.
Brain Region | Monoamine or Metabolite | Treatment |
|||||
---|---|---|---|---|---|---|---|
Vehicle –Vehicle | Vehicle –LNFPIII | PB/PM –Vehicle | PB/PM –LNFPIII | ||||
PFC | 5-HT | 1.28 ± 0.30 | 2.23 ± 0.56 | 1.51 ± 0.28 | 1.37 ± 0.29 | ||
5-HIAA | 2.51 ± 0.12 | 2.46 ± 0.19 | 2.79 ± 0.31 | 2.64 ± 0.27 | |||
DA | 0.37 ± 0.07 | 0.26 ± 0.13 | 0.52 ± 0.21 | 0.24 ± 0.11 | |||
HVA | 0.70 ± 0.27 | 0.43 ± 0.16 | 1.40 ± 0.48 | 0.65 ± 0.21 | |||
STR | 5-HT | 2.50 ± 0.48 | 3.02 ± 0.62 | 1.72 ± 0.39 | 3.05 ± 0.30 | ||
5-HIAA | 3.15 ± 0.47 | 2.55 ± 0.16 | 3.65 ± 0.46 a | 3.68 ± 0.32 a | |||
DA | 97.62 ± 2.91 | 106.60 ± 3.82 | 102.23 ± 6.36 | 95.02 ± 3.95 | |||
HVA | 9.03 ± 0.46 | 9.25 ± 0.53 | 11.63 ± 1.34a | 10.24 ± 0.53a | |||
AMY | 5-HT | 3.80 ± 0.81 | 4.37 ± 0.37 | 4.30 ± 0.60 | 3.39 ± 0.75 | ||
5-HIAA | 3.65 ± 0.43 | 3.49 ± 0.34 | 4.91 ± 0.42a | 4.25 ± 0.44a | |||
DA | 17.15 ± 3.79 | 25.01 ± 5.28 | 16.08 ± 4.44 | 19.02 ± 6.23 | |||
HVA | 2.79 ± 0.71 | 2.87 ± 0.27 | 2.79 ± 0.44 | 2.84 ± 0.67 | |||
dHip | 5-HT | 1.25 ± 0.33 | 1.69 ± 0.23 | 1.41 ± 0.22 | 1.59 ± 0.17 | ||
5-HIAA | 2.96 ± 0.22 | 3.32 ± 0.60 | 3.99 ± 0.44 a | 4.36 ± 0.59 a | |||
DA | 0.24 ± 0.08 | 0.26 ± 0.05 | 0.20 ± 0.06 | 0.14 ± 0.04 | |||
HVA | 0.15 ± 0.02 | 0.20 ± 0.04 | 0.25 ± 0.06 | 0.25 ± 0.08 |
Data are presented as mean ± SEM; unit: ng/mg protein; n= 6 per group.
a, b or c indicate significant main effect for GWI treatment (PB/PM), LNFPIII treatment or Treatment (GWI x LNFPIII) interaction, respectively, after a two-way ANOVA (p ≤ 0.05) and are bolded.
Italicized values indicate trend (p < 0.10) for main effect. Abbreviations: PFC: prefrontal cortex; NAc: nucleus accumbens; STR: striatum; AMY: amygdala; dHip: dorsal hippocampus; vHip: ventral hippocampus; 5-HT: serotonin; 5-HIAA: 5-hydroxyindoleacetic acid; DA: dopamine; HVA: homovanillic acid; PB: pyridostigmine bromide; PM: permethrin; LNFPIII: lacto-N-fucopentaose III.